Overview of the Global Systemic Lupus Erythematosus Pipeline and the Next Three Potential Product Launches


RELEASE DATE
22-Feb-2013
REGION
Global
DELIVERABLE TYPE
Market Research

RESEARCH CODE
9837-00-55-00-00
SKU
LS00066-GL-MR_16907
Yes
SHARE

Overview of the Global Systemic Lupus Erythematosus Pipeline and the Next Three Potential Product Launches
Published on: 22-Feb-2013 | SKU: LS00066-GL-MR_16907

Need more details?

$1,500.00

$1,125.00 save 25 %

DownloadLink
Need more details?

This research service provides an introduction to systemic lupus erythematosus (SLE), disease classification and diagnosis. Research in this report overviews the current status of SLE pipeline candidates with a focus on current Phase 3 candidates, detailed timelines with accrual rate and approval estimates for U.S. and European markets, ranking of the approval likeliness for current Phase 3 candidates, rationale for pivotal program design, Phase 2 data review, and KOL commentary. A pipeline assessment is provided for all active SLE candidates in development.

Executive Summary

Methodology and Scope

Introduction

Competitive Landscape

Timeline Transparency

SLE Drug Trial Results

Product Dashboards

The Future of Treatment Decisions

Appendix

The Frost & Sullivan Story


Have questions about this research or need deeper insights?
Speak directly with our analytics experts for tailored recommendations.

Recent related industry research

17 Sep 2026   |   Asia Pacific   |   Frost Radar

Frost Radar™: Facility Management in Malaysia, 2026

Malaysia's facility management (FM) market is transitioning from labor-intensive, compliance-driven service delivery to technology-enabled, outcome-oriented, and sustainability-integrated operating models. Competitive differentiation increasingly depends on providers’ ability to combine integrated F...

17 Sep 2026   |   Global   |   Market Research

Growth Opportunities in the Western Europe Consumer eSIM Market, 2026–2029

The consumer eSIM market in Western Europe is growing steadily, supported by the rising availability of eSIM-capable devices, particularly smartphones, and expanding travel-related use cases. However, commercialization has yet to translate into mass adoption. Despite Apple’s global launch of an eSIM...

17 Sep 2026   |   Asia Pacific   |   Frost Radar

Frost Radar™: ASEAN Warehouse Automation System Providers, 2026

Warehouse automation has moved from a discretionary capital project to a core operating capability. ASEAN operators are redesigning fulfillment networks around smaller orders, shorter delivery windows, broader stock keeping unit (SKU) ranges, and sharper demand volatility. Manual operations remain v...

16 Sep 2026   |   North America   |   Customer Research

US Automotive Technicians’ Choice Survey, 2025

The 2025 US Automotive Technicians’ Choice study is an insightful voice-of-customer survey that highlights the tool preferences of automotive aftermarket service technicians. The survey of 400 automotive technicians across the United States used a combination of computer-assisted telephone and compu...

16 Sep 2026   |   Global   |   Market Research

Apple Performance Tracker, Q1 2026

This Frost & Sullivan tracker provides metrics on Apple's quarterly performance (for both unit sales and revenues) for iPads, iPhones, Macs, and other products, such as iPods, Apple TVs, Beats Electronics, and Apple-branded and third-party accessories. It includes historical quarterly data for all t...

 

Purchase includes:
  • Report download
  • Growth Dialog™ with our experts

Growth Dialog™

A tailored session with you where we identify the:
  • Strategic Imperatives
  • Growth Opportunities
  • Best Practices
  • Companies to Action

Impacting your company's future growth potential.

This issue of Vital Signs discusses the change in 2015 Mammogram Guidelines, NeoGenomics' acquistion of Clarient from GE, and Tute Genomics' acquisition of Knome.
More Information
Deliverable Type Market Research
No Index Yes
Podcast No
WIP Number 9837-00-55-00-00
Is Prebook No

Overview of the Global Systemic Lupus Erythematosus Pipeline and the Next Three Potential Product Launches

$1,500.00

Special Price $1,125.00 save 25 %

In stock
SKU
LS00066-GL-MR_16907